Clinical test data for Neurontin may have been manipulated regarding its effectiveness for unapproved, off-label uses, according to documents produced in a lawsuit reports bloomberg.com, "Data From Studies of Pfizer Neurontin Drug May Have Been Skewed."

A report in the New England Journal of Medicine will reflect that data from Neurontin clinical trials that made it into medical journals was different than that produced in the original trials.  The article is "Outcome Reporting in Industry-Sponsored Trials of Gabapentin for Off-Label Use." 

Pfizer paid $430 million in civil penalties in 2004 for pumping doctors to prescribed Neurontin for off-label uses.